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Abstract
The family Flaviviridae comprises a wide variety of viruses that are distributed worldwide, some of which are
associated with high rates of morbidity and mortality. There are neither vaccines nor antivirals for most flavivirus
infections, reinforcing the importance of research on different aspects of the viral life cycle. During infection,
cytoplasmic accumulation of RNA fragments mainly originating from the 3′ UTRs, which have been designated
subgenomic flavivirus RNAs (sfRNAs), has been detected. It has been shown that eukaryotic exoribonucleases are
involved in viral sfRNA production. Additionally, viral and human small RNAs (sRNAs) have also been found in
flavivirus-infected cells, especially microRNAs (miRNAs). miRNAs were first described in eukaryotic cells and in a
mature and functional state present as single-stranded 18–24 nt RNA fragments. Their main function is the repression
of translation through base pairing with cellular mRNAs, besides other functions, such as mRNA degradation. Canonical
miRNA biogenesis involves Drosha and Dicer, however miRNA can also be generated by alternative pathways. In the
case of flaviviruses, alternative pathways have been suggested. Both sfRNAs and miRNAs are involved in viral infection
and host cell response modulation, representing interesting targets of antiviral strategies. In this review, we focus on
the generation and function of viral sfRNAs, sRNAs and miRNAs in West Nile, dengue, Japanese encephalitis, Murray
Valley encephalitis and yellow fever infections, as well as their roles in viral replication, translation and cell
immune response evasion. We also give an overview regarding other flaviviruses and the generation of cellular
miRNAs during infection.
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Background
MicroRNAs (miRNAs) are a class of molecules first
observed in 1993 in Caenorhabditis elegans, where it was
shown that the level of LIN-14 protein was regulated by a
22 nucleotide (nt) small RNA (sRNA) transcript generated
from the gene lin-4 [1]. Further studies in Caenorhabditis
elegans characterized a second sRNA originating from the
gene let-7, which suppressed lin-14, lin-28, lin-41, lin-
42 and daf-12 heterochronic gene expression [2].
Moreover, it was observed that the let-7 sRNA se-
quence is conserved among many species, suggesting a
putative function for this sRNA [3]. These small single-
stranded RNA molecules (18–21 nt) that were first
described as sRNA are presently known as miRNAs [4].
Eukaryotic miRNAs are generated by transcription of
the cellular genome through different pathways, and
more than 2000 human miRNAs have already been identi-
fied [5]. In addition, there is evidence for 1098 novel
human miRNA candidates [6]. miRNA genes (miR genes)
are located in variable genome regions, such as the in-
tronic or exonic sequences of protein-coding genes and
intronic or exonic sequences of noncoding RNAs [7]. The
majority of intronic miRNAs within protein coding genes
are transcribed by the same promoter of the gene. How-
ever, approximately one-third of intronic miRNA tran-
scripts have independent promoters, indicating that they
may be transcribed by a separate and controlled mechan-
ism or pathway [8]. In this regard, common features of
known RNA polymerase II and III promoters, such as
transcription start sites, CpG islands, conserved tran-
scription factor binding sites and A/B box sequences,
have been identified upstream of intronic miRNAs and
are predicted to function independent of host gene
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transcription [9]. All these features indicate that miRNA
expression may be regulated by transcription factors,
enhancers, silencing elements and chromatin modifica-
tion [10].
miRNAs can be found in plants, fungi, mammals and
viruses [11]. In viruses, miRNA production depends on
the eukaryotic cell machinery and viral genome com-
position: DNA or RNA [12]. The first report that de-
scribed miRNAs of viral origin used a cell line infected
with Epstein-Barr virus, a DNA virus [13]. Since this re-
port, studies employing DNA viruses to investigate viral
miRNA generation and function have increased sub-
stantially. On the other hand, there are fewer studies
investigating viral miRNA from cells infected with RNA
viruses [14–16]. Therefore, we gathered here the published
information on non-coding RNA (viral subgenomic RNAs,
viral small RNAs, viral miRNAs and human miRNAs) syn-
thesis and function during flavivirus infections. First, it is
important to review some concepts on miRNA biosyn-
thesis and function in eukaryotic cells.
Eukaryotic microRNA biogenesis and functions
miRNA biogenesis
In canonical biogenesis, miRNAs are transcribed from
miR genes as a primary miRNA (pri-miRNA) transcript
by RNA polymerase II, the same enzyme that catalyses
cellular mRNA transcription. Similar to cellular mRNA,
the pri-miRNA has a cap at the 5′ end and a polyadeny-
lated tail at the 3′ end [17]. This first transcript is longer
than 70 nt [18] and is frequently several kilobases, bears
one or more hairpin structures and can be processed
into one or several distinct miRNAs (polycistronic tran-
scription unit) [7] (Fig. 1). This initial transcript is metabo-
lized by a microprocessor complex containing the RNase
III Drosha and the co-factor DiGeorge critical region 8
(DGCR8), originating a second transcript named pre-
cursor miRNA (pre-miRNA) [19]. This process occurs
cotranscriptionally, as evidenced by the processing of
miRNAs from unspliced introns [20, 21]. DGCR8
appears to be able to recognize the target RNA, pri-
miRNA, through interactions with the ssRNA-dsRNA
junction (SD junction) as well as the stem of the hairpin.
This interaction directs Drosha activity, enabling the
cleavage of the pri-miRNA at an approximately 11 bp site
from the SD junction, generating a hairpin structure of
approximately 65 nt, pre-miRNA [22–24] (Fig. 1). The
pre-miRNA is then recognized and exported from the
nucleus by exportin-5, a nucleocytoplasmic transport
factor, in a Ran-GTP dependent manner [25]. Once in
the cytoplasm, the pre-miRNA has the loop structure
removed, releasing a dsRNA of approximately 22 nt.
This process is mediated by a complex composed of the
RNase III Dicer, which mediates the cleavage, and a
dsRNA-binding protein (TRBP or PACT) [7]. The dsRNA
is incorporated into the pre-RNA induced silencing com-
plex (pre-RISC), where strand selection based on the
thermodynamic properties of the duplex takes place. One
strand is degraded in the cytoplasm (passenger strand,
miRNA*) and the other strand (guide strand, miRNA) re-
mains incorporated in the RISC, which has a protein from
the Argonaute family (Ago1-4) as its core constituent
[26]. All Ago proteins, in association with the miRNA
guide, can repress mRNA translation [26], but only Ago2
has the ability to cleave the target mRNA in mammals
[27]. Through base pairing, miRNAs have the ability to
form dsRNA with cellular mRNA and may either suppress
its translation or induce its degradation [28]. The inter-
action of miRNA:mRNA is strongly dependent on nucleo-
tides 2-8 located at the 5′ end of the miRNA; this region
is named the seed sequence or seed region [29]. Usually,
the seed region binds to the 3′ untranslated region (UTR)
of cellular mRNA, but it can also bind to other regions,
such as exons [30].
There are some miRNAs that are generated by different
routes, in which not all proteins and factors used in the
canonical pathway are required. They can be generated by
Drosha/DGCR8- or Dicer-independent pathways. These
non-canonical Drosha/DGCR8-independent miRNAs can
be derived from introns, small nucleolar RNAs (snoR-
NAs), endogenous short hairpin RNAs (shRNAs) and
transfer RNAs (tRNAs) [31].
In vertebrates, despite the many reports of non-canonical
miRNA biogenesis pathways, most of the functional miR-
NAs seem to undergo canonical processing, and only ap-
proximately 1 % of conserved microRNAs are produced by
Drosha- or Dicer-independent pathways [32].
To distinguish between miRNA and siRNA, we con-
sidered that both molecules have interfering roles in
gene expression, either through perfect or imperfect
base pairing with the mRNA target [33]. Furthermore, in
mammalian cells, the RNA interference (RNAi) machin-
ery is shared by the miRNA and siRNA pathways, and
there is only one Dicer enzyme [34]. On the other hand,
in insect cells, the interfering machinery is separated. In
Drosophila cells, Dicer-1 is preferentially used to pro-
duce miRNA, while Dicer-2 is responsible for generating
siRNA [35]. The C6/36 cell line (from Aedes albopictus
mosquito), which will be referred to at many points in
this text, is RNAi defective due to the lack of Dicer-2 ac-
tivity [36].
miRNA functions
Among the key roles of miRNAs are gene expression con-
trol and mRNA degradation [37]. Complementing their
role in gene expression regulation, miRNAs also interact
with RNA-binding proteins (RBP), inhibiting the inter-
action between RBP and mRNA [38]. The classical func-
tion of miRNA is post-transcriptional gene expression
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control; thus, this molecule, besides being involved in the
regulation of physiological processes [39], can also be as-
sociated with pathological disorders [40, 41]. In addition,
miRNAs are present in blood and may be useful as bio-
markers for diagnosis and prognosis of several pathologies
[42–44]. miRNAs are also involved in somatic cell repro-
gramming or pluripotent cell maintenance [45], cell cycle
control [46], erythropoiesis [47], apoptosis [48, 49], neuro-
genesis [50], insulin secretion [51], cholesterol metabolism
[52], immune responses [53] and viral replication [54].
Interestingly, it has also been shown that miRNAs have
roles similar to cellular messengers and signalling mole-
cules [55]. Fabbri et al. [55] showed that specific miRNAs
(from tumour cell lines) bind to murine toll-like receptor
(TLR)-7 and human TLR-8 in immunological cells, indu-
cing the activation of nuclear factor kappa B (NF-kB) and,
consequently, the production of prometastatic inflam-
matory cytokines. Furthermore, viral miRNAs pro-
duced during viral infection may inhibit the viral
immune response, which includes inhibiting cytotoxic
lymphocyte recognition and modulating the expression
of cytokines and chemokines of infected cells [56].
sfRNA and miRNA in flavivirus infection
Flaviviruses are small spherical viruses of approximately
50 nm with an electron-dense core of approximately
30 nm, surrounded by a lipid envelope composed by two
viral proteins: envelope (E) and membrane (M) [57]. The
envelope mediates the binding and fusion during viral in-
fection and is the major antigenic determinant, whereas
the M protein is a small proteolytic fragment of the prM
protein. The flavivirus genome consists of a positive
ssRNA containing a cap at its 5′ end but no poly-A tail
at its 3′ end. It has a single open reading frame (ORF)
flanked by UTRs at its 5′ and 3′ ends [58]. Although
both UTRs of flavivirus RNA exhibit great variability,
conserved regions and secondary structural conforma-
tions are found [59]. Their functions are not completely
clear, but they are involved in viral translation, tran-
scription and replication regulation [60, 61]. The UTRs
Fig. 1 Canonical miRNA biogenesis. miRNAs are transcribed by RNA polymerase II from miR genes into a pri-miRNA transcript (> 70 nt), which is
metabolized by a microprocessor complex (Drosha and DGCR8), forming the pre-miRNA (~65 nt). The pre-miRNA is then exported from the nucleus
by exportin-5 in a Ran-GTP dependent manner. Once in the cytoplasm, it is processed into a dsRNA of ~22 nt by a complex composed of Dicer and a
dsRNA-binding protein (TRBP or PACT). Then, this dsRNA is incorporated into the pre-RISC, where strand selection takes place: one strand is degraded
(passenger strand, miRNA*) and the other strand (guide strand, miRNA) remains incorporated in the RISC. Through base pairing, miRNAs can form
dsRNA with cellular mRNA, usually at the 3′ UTR region, and may either suppress its translation or induce its degradation. Figure by Wagner Nagib de
Souza Birbeire
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may contain binding sites for viral and cellular proteins
and sequences for RNA cyclization [62–64]. Interest-
ingly, flaviviruses transmitted by mosquitoes and ticks
have different sequences and secondary structures
(hairpin loop) in the 3′ UTR, probably representing an
adaptation to the vector [65–67]. The translation of the
single ORF of the flavivirus RNA genome produces a
large polyprotein cleaved co- and post-translationally
by viral and host proteases [68]. The polyprotein is
cleaved into 10 proteins, three of which are structural
(C, prM and E) and located in the N-terminal region
and seven of which are nonstructural proteins (NS):
NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5 [58].
All these features are shared among the members of
the flavivirus genus: Japanese encephalitis virus (JEV),
Murray Valley encephalitis virus (MVEV), West Nile
virus (WNV), dengue virus (DENV), yellow fever virus
(YFV), tick-borne encephalitis virus (TBEV) and Saint
Louis encephalitis virus (SLEV), just to mention a few.
In the last few decades, with the development and im-
provement of molecular biology, microarray and next-
generation sequencing techniques, new small non-coding
RNAs and miRNAs have been discovered and character-
ized. The possibility of RNA viruses, which do not possess
a nuclear DNA stage in their replication cycle, encoding
miRNAs once the first steps in miRNA biogenesis take
place in the nucleus has been highly discussed. To investi-
gate this possibility, Rouha et al. [69] modified the TBEV
(strain Neudoerfl) genome by genetic engineering. This
modification consisted of the insertion of a known heter-
ologous miRNA hairpin precursor from herpesvirus 4
(miR-BART2) in the 3′ UTR of a wild-type TBEV strain.
The mutant and wild-type TBEV were introduced into
BHK-21 cells by electroporation, and the levels of miR-
BART2 were measured by real time PCR and Northern
blotting. The results showed an increase in this miRNA
24 and 48 h post infection (hpi). To investigate the role of
Drosha, the authors knocked down Drosha protein ex-
pression and observed that it was involved in this process.
Therefore, this work corroborates the thesis that RNA
viruses with an exclusively cytoplasmic replication cycle
have the potential to encode functional miRNAs [69].
In support of this idea, Shapiro et al. [70], using a different
model (recombinant Sindbis virus producing miRNA), sug-
gested the existence of a cytoplasmic microprocessor of
pri-miRNAs and showed that RNA viral infection induced
Drosha relocalization to the cytoplasm.
Viral UTRs have hairpin structures that are believed to
act as pre-miRNAs, which can be processed by Dicer or
Ago cellular proteins, originating a mature and func-
tional miRNA-like molecule that may contribute to virus
and host cell mRNA regulation. Consequently, it has
been suggested that viral miRNA biogenesis is Drosha-
independent because RNA virus replication takes place
in replication complexes located in the cytoplasm, and
Drosha is located in the nucleus [15, 16]. RNA viruses
are susceptible to degradation by the host RNA decay
machinery, and the viral suppression of host exonucle-
ases is crucial for viral pathogenesis [71–74]. In addition,
as a consequence of host cell response against the viral
infection, several exonucleases and endonucleases are
produced to circumvent the accumulation of viral RNAs
in the cytoplasm [71]. Therefore, the viral fragments
generated by exonucleases, such as subgenomic flavivi-
rus RNAs (sfRNAs) derived from the 3′ UTR, are sug-
gested as one of the sources for viral miRNAs [15, 16]
and are required to repress the cellular RNA decay ma-
chinery [75–77]. A hypothetical model of flavivirus
miRNA-like sRNA biogenesis is presented in the Fig. 2.
To understand the role of viral miRNAs, it is important
to briefly introduce the sfRNAs, which are also generated
during viral infection. sfRNAs can act as decoy molecules
for Dicer and Ago2 [78] or as a source of viral miRNAs
[75]. The generation of sfRNAs from flaviviruses was first
characterized during Murray Valley viral infections [79]
and was later found in Japanese encephalitis virus [80] and
West Nile virus [81] infections. However, Pijlman et al.
[82] was the first to characterize a host 5′- 3′ exoribonu-
clease 1 (XRN1) degrading the viral genomic RNA and,
consequently, potentially generating sfRNAs (from the 3′
UTR) during West Nile, yellow fever and dengue virus in-
fections. In flavivirus RNA, the 5′ end of the 3′ UTR has
conserved secondary structures where the XRN1 stalls,
resulting in incomplete degradation of the genomic RNA
and generation of the sfRNAs [82, 83]. The sfRNAs, in
turn, are able to generate viral miRNA-like molecules
through a non-canonical pathway [15, 16]. Further details
on the mechanism and structures involved in the gener-
ation of sfRNAs can be found at Chapman et al. [84] and
Chapman et al. [85].
All available information regarding flavivirus-derived
sfRNAs and virus-derived small RNAs (vsRNAs) by the
time of submission of this manuscript is summarized in
Table 1. In the following sections, more detailed infor-
mation on West Nile, dengue, Japanese encephalitis,
Murray Valley encephalitis and yellow fever viruses will
be presented. Experiments that were carried out solely
in silico are not included in Table 1.
West Nile virus
The West Nile virus (WNV) distribution includes temper-
ate and tropical regions of the world. Birds are commonly
infected and serve as the prime host reservoir. WNV is
transmitted to vertebrates during the female blood meal
of various species of Culex sp. mosquitoes, e.g., Culex
pipiens, Culex tarsalis and Culex quinquefasciatus,
depending on the geographical area. Clinical symp-
toms of WNV infection may include fever, myalgias
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and meningoencephalitis. WNV infection can progress to
a neuroinvasive disease characterized by encephalitis [86].
WNV is one of the most studied flavivirus regarding the
generation of sfRNAs, sRNAs and miRNAs. The first re-
port of sfRNAs from WNV infection was during a study
on the role of RNase L in the antiviral response to WNV
(Eg101 strain). Using MEFs from flavivirus-resistant mice
(C3H.PRI-Flvr) and susceptible mice (CH3/HeJ) infected
with WNV, a band of approximately 600 nt was detected
by Northern blot hybridization in both cells. In the ab-
sence of RNase L, in MEF cell lines derived from trans-
genic C57BL/6 RNase L-/- mice, a similar band was also
detected. These results indicate that RNase L was not re-
sponsible for the generation of the sfRNAs that had been
detected [81]. Later, sfRNAs of viral origin were also iden-
tified in mammalian cell lines (BHK-21) infected with
WNV (Kunjin and NY99 strain), and it was postulated
that these non-coding sfRNAs are generated by degrad-
ation of the viral genomic RNA by cellular exoribonu-
cleases, such as XRN1. The authors showed that the
generation of these sfRNAs in WNV facilitated not only
viral replication but also cytopathic effects in cell culture
and promoted viral pathogenicity in mice [82]. In addition,
Schuessler et al. [87] observed that the synthesis of these
sfRNAs by WNV (Kunjin strain) in MEFs and mice might
be associated with the escape from the antiviral response
mediated by type I interferon (IFN-I). Although the mech-
anism by which WNV sfRNAs inhibit the function of
IFN-I is not completely understood, it has been suggested
that sfRNAs directly interact with or antagonize IFN-
stimulated gene (ISGs) products (for example, protein kin-
ase R and RNase L) that bind RNAs [87]. Additionally, a
suppressor role in the RNAi response to viral infection in
mammalian and insect cells has also been ascribed to
these sfRNAs [78, 88]. While investigating how the WNV
escapes RNA silencing cell defences, Schnettler et al. [88]
observed that nonstructural viral proteins (which have
dsRNA-binding domain) do not act as RNAi suppressors
during WNV (replicon) replication, as observed for other
viruses. On the other hand, WNV sfRNA was able to sup-
press cellular siRNA and miRNA induced in infected cells
through competition with Dicer substrates [88].
Parameswaran et al. [89] identified small RNA popula-
tions by high-throughput sequencing of six RNA viruses
(hepatitis C, polio, dengue, vesicular stomatitis, Flock
House and West Nile) during animal cell infection. The
abundance and molecular features of vsRNAs (<200 nt)
generated by the cell silencing pathway machinery were
dependent on the nature of the host and/or virus. The
abundance of vsRNAs with regard to host miRNAs was
Fig. 2 Hypothetical model of flavivirus miRNA-like sRNA biogenesis. Flavivirus genomic RNA is released into the cytoplasm where viral replication
and translation take place. In the cytoplasm this RNA may undergo processing by the exonuclease XRN1, which is part of the mRNA decay machinery,
and generate the sfRNA. The sfRNA in turn may be further processed into a pre-miRNA-like molecule by a cytoplasmic microprocessor containing
Drosha whose relocalization to the cytoplasm may take place during viral infection. The flavivirus genomic RNA or replication intermediates may also
be recognized by pattern recognition receptors and activate the innate immune response system. As a consequence, viral genomic RNA can be
degraded in several fragments by endo and/or exonucleases. These viral RNA fragments depending on their size and structure may either be
processed by Dicer or directly incorporated into RISC. Figure by Wagner Nagib de Souza Birbeire
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Table 1 Viral sfRNA and small RNA in flavivirus infection.
Virus sfRNA Small RNAa Host system Function Reference
WNV 600 nt MEF Scherbik et al., 2006
WNV 525 nt BHK-21 and mice Facilitated viral replication
and viral pathogenicity
Pijlman et al., 2008
WNV 525 nt MEF and mice Viral evasion Schuessler et al., 2012
WNV (replicon) Vero, BHK-21, S2, U4.4
and Ap61
Suppression of RNAi machinery Schnettler et al., 2012
WNV 19 – 29 nt Culex (pipiens) quinquefasciatus Brackney et al., 2009
WNV 19, 21 and 28 nt DC from WT mouse,
lymph node and spleen
cells from IFNRab−/− mice
Possible involvement with
IFN response
Parameswaran et al., 2010
WNV KUN-miR-1 (21 nt) C6/36, Aag2 Targets GATA4 mRNA Hussain et al., 2012
DENV-2
(replicon)






180, 270, 429 nt
410 nt
390 nt
Vero, BHK-21, A549, HepG2,
C6/36 and mouse brain
Possible role in viral life
cycle and pathogenesis
Liu et al., 2010
DENV-2 429 nt Vero and BHK-21 Cytopathogenicity and apoptosis Liu et al., 2014
DENV-2 Huh7 Interference with translation of
antiviral interferon-stimulated mRNAs
Bidet et al. 2014
DENV-2 Huh7 and primary monocytes sfRNA binds TRIM25 Manokaran et al., 2015




Aag2 and Aedes aegypti
Scott et al., 2010
DENV-2 13-19 nt
24–30 nt
Aedes aegypti Hess et al., 2011







Aag2, C6/36 and Vero
Regulation of RNA replication
by targeting NS1 (vsRNA-5)





Schirtzinger et al., 2015
JEV 521 - 523 nt BHK-21 and C6/36 Modulation of viral replication Lin et al., 2004
JEV BHK-21 Regulation of viral RNA replication and
translation
Fan et al., 2011
JEV BHK-21, C6/36 and A549 Inhibition of the induction of IFN-beta Chang et al., 2013
MVEV 600 nt Brain of infected mice
(C3H/HeJ and C3H/RV) and Vero
Urosevic et al., 1997
MVEV 500 nt BHK-21 Pijlman et al., 2008
YFV 300 nt BHK-21 Pijlman et al., 2008





Silva et al., 2010
SRV 500 nt BHK-21 Pijlman et al., 2008
TBEV 22 nt IDE8 Schnettler et al., 2014
LGTV 22 nt IDE8 Schnettler et al., 2014
Grey specifies the molecule found and the respective host system
Abbreviations: DENV Dengue virus; JEV Japanese encephalitis virus; LGTV Langat virus; MVEV Murray Valley encephalitis virus; SRV Saumarez Reef virus; TBEV Tick-borne
encephalitis virus; WNV West Nile virus; YFV Yellow fever virus
Host system: A549 (Human lung carcinoma cell line), Aag2 (Aedes aegypti cell line), Ap61 (Aedes pseudoscutellaris cell line), BHK-21 (Baby hamster kidney fibroblast
cell line), C6/36 (Aedes albopictus cell line), HepG2 (Human hepatocellular carcinoma cell line), Huh7 (Human hepatocarcinoma cell line), IDE8 (Ixodes scapularis-
derived cell line), MEF (Mouse embryonic fibroblast cell line), S2 (Drosophila melanogaster Schneider-2 cell line), SW13 (Human adrenal carcinoma cell line), U4.4
(Aedes albopictus cell line), Vero (Kidney epithelial cells from African green monkey).
aAll information on small RNAs and miRNAs with either no function described or functionally characterized were included
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higher with a lack of a functional IFN-α/β receptor in
murine cells infected with WNV (NY99-eqhs strain).
vsRNAs were also detected in infected dendritic cells
from wild-type mice. In these conditions, it was possible
to detect three sizes of vsRNAs, 19, 21 and 28 nt. The
role or functional activities of vsRNAs were not assessed
in this work [89]. Two years later, Hussain et al. [15] re-
ported the generation of miRNA-like sRNAs from WNV
using mosquito cells (Aag2 cells, from Aedes aegypti and
RNAi-defective C6/36, from Aedes albopictus) infected
with WNV (Kunjin strain). This was the first report
demonstrating the generation of functional viral miR-
NAs during a flavivirus infection. The miRNA discov-
ered by Hussain et al. [15] was named KUN-miR-1 and
was found to be derived from the 3′ SL region of WNV
RNA. Using a bioinformatics prediction approach, they
were able to identify a pre-miRNA hairpin structure at
the 3′ UTR of the WNV genome using the VMir soft-
ware. Based on this prediction, it was possible to design
probes for Northern blot analysis, which confirmed the
presence of the pre-miRNA (70 nt) and mature miRNA
(21 nt) in infected mosquito cells (C6/36 and Aag2). In
this model, the Dicer-1 enzyme was shown to be respon-
sible for KUN-miR-1 biogenesis. When the Dicer-1 gene
was silenced, KUN-mir-1 production declined, and a
significant reduction in WNV replication was also ob-
served. Finally, the function and potential target of
KUN-miR-1 in the host cell, in this case Aag2, were
identified by a new method where KUN-miR-1 was used
as a reverse complementary primer to amplify (RT-PCR)
the mRNA to which KUN-miR-1 binds. The alignment
of the amplified sequence against the Aedes aegypti gen-
ome revealed the transcription factor GATA4 mRNA as a
target for KUN-miR-1. Evidence shows that KUN-mir-1
increases GATA4 mRNA accumulation in infected cells. It
was also shown that the silencing of GATA4 mRNA leads
to a decay in WNV RNA, suggesting a role for this gene
product in the regulation of viral replication [15].
Dengue virus
Dengue is an arboviral disease that has a high impact on
public health worldwide. It is caused by the four serotypes
(DENV1-4) of the virus and is transmitted to humans
mainly by the female Aedes aegypti infected with DENV.
Symptoms during the early stage include fever, malaise,
headache, body pain and rash. Dengue fever can progress
to severe conditions, such as dengue haemorrhagic fever
(DHF) and dengue shock syndrome (DSS) [90].
As previously cited, Pijlman et al. [82] has shown that fla-
viviruses produce a noncoding RNA nuclease-resistant
sfRNA during cell infection. BHK-21 cells infected with a
DENV-2 replicon also produced a sfRNA of approximately
400 nt, which correlates with the one of the corre-
sponding 3′ UTR. Several years later, Liu et al. [91]
demonstrated the production of sfRNA in several per-
missive cells (Vero, BHK-21, A549, HepG2, C6/36 cell
lines) infected with all four serotypes of dengue
(DENV-1, 128 strain; DENV-2, New Guinea C, 43, Fj10
and Fj14 strains; DENV-3, 80 strain; DENV-4, B5 strain).
Curiously, the amount of sfRNA produced was not the
same for all cells. sfRNA was also identified in brain tissue
from mice infected with the different dengue serotypes.
Overall, the viral genomic sequence required for sfRNA
production is conserved in all serotypes. However, the size
of the sfRNAs differed for each serotype: 430 nt for
DENV-1, 429 nt for DENV-2 (strain 43 also produced two
smaller sfRNAs of 180 and 270 nt), 410 nt for DENV-3
and 390 nt for DENV-4. It is worth noting that these
sfRNAs are derived from the 3′ UTR, a region of the viral
genome known to be rich in secondary structures and
functional RNA elements important for viral replication
and translation [91]. The production of a sfRNA of 429 nt
in size was reported by Liu et al. [92] in experiments using
Vero cells infected with DENV-2 (TSV01 strain). This
sfRNA was detected up to 48 hpi in Vero and BHK-21
cells, and the viral RNA structure responsible for the
sfRNA generation was identified in the 3′ UTR [92].
These observations matched previous results [91]. Add-
itionally, it was observed that mutations (i.e., deletions) in
the sfRNA sequence at the 3′ UTR had no significant ef-
fects on viral translation, replication or viral lifecycle.
sfRNA production was shown to be required for viral
cytotoxicity and apoptosis induction in these infected cell
cultures. The mechanism responsible for apoptosis induc-
tion in infected mammalian cells was found to be caspase-
3-dependent and possibly involves the PI3K-AKT signal-
ling pathway and Bcl-2 as a downstream mediator [92]. In
addition, during viral infection, the accumulation of RNA
molecules in host cells can activate the RNA decay ma-
chinery [72] and trigger an antiviral response [74]. Regard-
ing this subject, Bidet at al. [93] have shown that the
sfRNA generated during DENV-2 (New Guinea C strain)
infection of a hepatocarcinoma cell line (Huh7) was able
to antagonize host RNA-binding proteins (G3BP1, G3BP2
and CAPRIN1) and regulate ISGs expression, conse-
quently avoiding the antiviral IFN-mediated response.
Thus, another proposed role for DENV-2 (New Guinea C
strain) sfRNAs is the regulation of the host cell antiviral
state by circumventing IFN action. In summary, sfRNAs
can bypass the host cell response by acting as decoy (or
sponge) molecules to the RNA decay machinery, Dicer,
factors and proteins involved in immune response and
antiviral signalling (such as the RNAi machinery and ISGs
mRNA translation) [88, 93, 94]. Recently, Manokaran et
al. [95] proposed a model to explain DENV-2 sfRNA-
mediated epidemiological fitness. In this study, DENV-2
belonging to different clades (PR-1 and PR-2B) identified
in Puerto Rico during the 1994 epidemic were evaluated.
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In this context, the authors investigated the molecular
mechanism behind the PR-2B spread and why this clade
replaced PR-1. DENV-2 PR-2B produced increased levels
of sfRNA relative to genomic RNA (sfRNA/genomic RNA
ratio) compared to DENV-2 PR-1 during viral replication
in the Huh7 cell line. The 3′ UTR sequence from DENV-
2 PR-2B had three nucleotide substitutions, which con-
tributed to the greater accumulation of sfRNAs compared
with PR-1. Manokaran et al. [95] investigated the inter-
action between host proteins and sfRNAs, employing
stable isotope labelling of amino acids in cell culture
coupled with quantitative mass spectrometry, and two
proteins were identified as significantly enriched: tripartite
motif-containing 25 (TRIM25) and mitochondrial antiviral
signalling (MAVS). Although both proteins are in-
volved in signalling for IFN expression, when the au-
thors performed an immunoprecipitation to detect
TRIM25 or MAVS in infected cells, only sfRNAs
from DENV-2 PR-2B were enriched (associated) with
TRIM25, confirming the mass spectrometry results. In
conclusion, the clade replacement of DENV-2 PR-1
was attributed to the increased sfRNA production and
sequence composition of PR-2B, which contributed to
circumvent IFN expression [95].
The first report on mammalian host RNAi and miRNA
pathway status during dengue virus infection showed
that Huh7 infected with DENV-2 (INDI-60 strain)
showed a decrease in the mRNA levels of Dicer, Drosha,
Ago1 and Ago2 24 and 48 hpi. Consequently, this af-
fected and decreased the host miRNA production. In
addition, an important role in the suppression of the
RNAi machinery in cells infected with any of the four
dengue virus serotypes was attributed to NS4B protein,
particularly its transmembrane domain 3 region
(TMD3), which interferes with Dicer activity [96].
Employing deep sequencing, Parameswaran et al. [89]
identified two vsRNAs (17 and 22 nt) in the Huh7 cell
line infected with DENV-2 (16,681 strain). Nevertheless,
there was no further information on whether these
vsRNAs are miRNAs or siRNAs derived from DENV or
their possible function [89]. In the same year, Scott et al.
[97] studied the production of DENV-2-specific vsRNAs
(Jamaica 1409 strain) in infected mosquitoes and mos-
quito cells by deep sequencing through analysis of small
RNA libraries. The authors investigated the vsRNA pro-
file using Aedes aegypti mosquitoes and two different
mosquito cell lines, Aag2 cells (RNA interference-
competent) and C6/36 (RNA interference-incompetent).
The predominant size of DENV-2-specific vsRNAs in
Aedes aegypti mosquitoes and the Aag2 cell library was
21 nt, and in the C6/36 cell library, it was 27 nt. In vitro
studies demonstrated that vsRNA production in C6/36
cells led to inefficient Dicer-2 cleavage of long dsRNAs.
These data suggest that the lack of a complete and
functional RNAi pathway in C6/36 cells may favour
arbovirus replication [97]. Considering the importance
of sRNAs in antiviral defence in mosquito cells, Hess et
al. [98] determined the vsRNA profile in Aedes aegypti
mosquitoes infected with DENV-2 (Jamaica 1409 strain).
Applying the deep sequencing technique, the vsRNAs
(20–23 nt) that had been previously reported by Scott
et al. [97] were confirmed. In addition, unusually small
RNAs (usRNA, 13–19 nt) and sRNAs presenting a size
(24–30 nt) consistent with PIWI pathway small RNAs
were also identified. These results suggest a role for
the PIWI pathway in the antiviral response in Aedes
aegypti [98].
In an attempt to elucidate the relationship between
the IFN response and the RNAi machinery, deep se-
quencing of mosquito (U4.4) and primate (Vero and
Huh7) cell lines infected with DENV-4 was carried out.
As initially expected, because RNAi is the major antiviral
response in insect cells, a much higher production of
vsRNAs was observed in U4.4 than Vero or Huh7 cells.
Two different mammalian cell lines, one capable of
mounting IFN-I responses (Huh7) and the other not
capable (Vero), were used to investigate the effect of IFN
responses on the vsRNA production in DENV-infected
cells. It was expected that DENV-4-infected Vero cells
would show a more extensive repertoire of vsRNAs than
DENV-4-infected Huh7; however, a significantly greater
percentage of vsRNAs were observed in Huh7 cells.
vsRNAs from DENV-4-infected U4.4 cells were mostly
21 nt and originated in a similar proportion from the
genome and antigenome. In the mammalian cells,
vsRNAs ranged from 12–36 nt with a modest peak at
24 nt, and most were derived from the positive-sense
strand. When the DENV-4 genome was mapped in
search of targets for the 21 nt vsRNAs identified in
DENV-4-infected Huh7 cells, a major peak was observed
at the 5′ end of NS5. In the case of DENV-4-infected
Vero cells, additional peaks were identified at the 5′ and
3′ ends of the E gene and at the 3′ end of NS5. All the
peaks observed in the mammalian cells could also be
found in the mosquito cells, although not always with
corresponding intensities. According to Schirtzinger et
al. [99], the characteristics of the vsRNAs found in the
mammalian cells broad size distribution and origin
mostly on the positive-sense strand suggest they are not
Dicer products [99].
Recently, two studies reported conflicting results re-
garding the existence of miRNAs derived from the
DENV genome. The first study investigated the 5′ UTR
and 3′ UTR from the genome of DENV-2 (New Guinea
strain) as candidate source sequences of viral miRNAs,
which are known for presenting stem-loop structures.
These structures could be potential targets for enzymes
belonging to the eukaryotic RNA silencing machinery.
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In this work, the miRNA analysis by deep sequencing
was first evaluated in infected Aedes aegypti mosquitoes.
RNAfold software was used for the prediction of precur-
sor stem-loop structures in the 5′ and 3′ UTRs of the
viral genome, which, together with the deep sequencing,
allowed the selection of six different miRNA-like mole-
cules (vsRNA1-6) for further analysis. After the infection
of Aag2 cells with DENV-2 and treatment with a syn-
thetic inhibitor specific to the vsRNA-5, one of the
selected vsRNA candidates, the authors observed a sig-
nificant increase in viral replication. The same results
were observed in C6/36 and Vero cell lines. vsRNA-5
was localized to the 5′ portion of the 3′ UTR, the main
protein involved in vsRNA-5 biogenesis in insect cells
was Ago2 and the DENV-2 NS1 gene was identified as
the vsRNA-5 possible target. The proposed role of
vsRNA-5 is the down-regulation of viral RNA replication
in this DENV-2 model [16]. On the other hand, Bogerd
et al. [100] reported that the infection of human cells
(Huh7) with DENV-4 (TVP 360 strain) or WNV does
not produce viral miRNAs. A sRNA library from DENV-
4-infected Huh7 cells did not show enrichment for any
particular length, such as the 22 ± 2 nt sizes predicted
for Dicer cleavage products. However, it is important to
note that when human Dicer-deficient cells generated
from the 293T cell line (NoDice) were infected with
DENV-4, the virus replication proceeded “slightly more
slowly” compared with wild-type 293T cells. In regard to
yellow fever and WNV infections in NoDice and normal
293T cell lines, no relevant difference in viral replication
was found. As the majority of vsRNAs detected in this
study originate from the positive RNA strand, these au-
thors suggest that they were the result of viral genome
breakdown [100].
Because the methodologies used to predict plant and
animal miRNAs cannot be accurately applied to viral
miRNAs, Ospina-Bedoya et al. [101] designed a different
approach to predict vsRNAs derived from the dengue
virus genome. This strategy involved scanning the gen-
ome in search of pre-miRNAs using the VMir software,
filtering these results with the ncRNA feature extraction
and pre-miRNA classification web tool, validating the
secondary structure of the pre-miRNAs using Mfold
and, at last, identifying mature miRNAs with the
MaturePred tool. Applying this methodology to the
DENV-2 genome (GenBank accession numbers:
JF357906.1 and FJ390389.1), they were able to identify
eight putative miRNAs, all derived from the negative
strand. These miRNAs are scattered throughout the viral
genome. The authors also note that most of these miR-
NAs do not start with a U at their 5′ end as would be
expected of miRNAs recognized by Ago1, which may in-
dicate a non-canonical pathway origin. Despite not car-
rying out any in vitro or in vivo validation of the
identified miRNAs, the analysis included a final step in
which the MiRanda software was used to search the hu-
man genome UTRs for functional targets. The result
was the identification of 53 target transcripts for these
eight miRNAs, suggesting that most of them have more
than one target. A functional enrichment analysis of
these potential targets showed the most enriched
functional clusters to be anatomical structure formation
involved in morphogenesis and cell projection morpho-
genesis [101]. It is worth noting that the in silico pre-
dicted miRNAs do not match those identified in vitro by
Hussain and Asgari [16]. Although both used the
DENV-2 New Guinea C strain, the results are quite
different.
Japanese encephalitis virus
Japanese encephalitis virus (JEV) is most prevalent in
temperate and tropical areas of eastern and southern
Asia. The virus transmission cycles involves wild birds
and domestic pigs as reservoirs. Among the major vec-
tors of JEV are the mosquitoes Culex tritaeniorhynchus.
The transmission to humans may cause symptoms such
as lethal meningomyeloencephalitis, but most human
infections are asymptomatic or induce influenza-like
symptoms as a mild febrile illness [102].
Lin et al. [80] characterized a specific plus-strand RNA
molecule of 521 to 523 nt in mammalian (BHK-21) and
mosquito (C6/36) cell lines infected with nine strains of
JEV (RP-2, RP-9, TP-53, CH-1392, CC-27, S-26, PC-806,
Beijing-1 and Nakayama). However, this molecule accu-
mulates more abundantly in mosquito cells than in
mammalian cells. This sfRNA, called a small RNA by
these authors, was found to be identical to the highly
conserved sequence at the 3′-terminal region of the 3′
UTR of all JEV strains. The authors speculated that the
transcription of JEV minus-strand RNA by an internal
promoter can generate the plus-strand JEV sfRNA. Al-
ternatively, the sfRNA molecule may also be a product
of viral genome cleavage by host RNases [80]. In a sub-
sequent work, the same group revealed preliminary evi-
dence suggesting that JEV sfRNA (RP-9 strain) could
modulate viral replication and translation. JEV sfRNAs
were detected from 28 to 48 hpi in infected BHK-21
cells. When sfRNA generation and accumulation (evalu-
ated by Northern blot) were compared with viral gen-
omic RNA and antigenomic RNA amounts (determined
by qPCR), the authors observed that sfRNA appearance
was correlated with the antigenome RNA plateau (from
32 to 40 hpi). This suggests that sfRNA may regulate
antigenome synthesis. To investigate the role of sfRNA
in JEV replication, plus- or minus-strand forms of the
sfRNA were transfected into JEV-infected cells. The
presence of minus-strand JEV sfRNA, in trans, in in-
fected BHK-21 cells increased antigenome JEV RNA
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synthesis. Thus, this result suggests that in trans minus-
strand sfRNA inhibited the JEV-derived plus-strand
sfRNA by complementarity. Consequently, it can be
concluded that sfRNA controls antigenome RNA synthe-
sis. When the viral translation was evaluated (by a
Renilla luciferase assay employing a JEV minicon con-
struction containing a Renilla luciferase reporter gene)
the addition of both, minus- or plus-strand sfRNAs
inhibited the luciferase translation [103]. Furthermore,
Chang et al. [104] showed that the ratio between JEV
sfRNA and genomic RNA (sfRNA:gRNA) was increased
in a later stage (5 dpi) compared with acute JEV (RP-9
strain) infection (48 hpi) in BHK-21 and C6/36 cell lines
(IFN-incompetent cells). When a JEV-infected IFN-
competent lung carcinoma cell line (A549) was trans-
fected with sfRNA, the expression of IFN-β decreased
significantly. The IFN-β inhibition was possibly due to
the role of sfRNA (dose-dependent response) in prevent-
ing the phosphorylation of the interferon regulatory
factor-3 (IRF-3) transcription factor and its nuclear
translocation. In addition, JEV-infected cells transfected
with sfRNA had reduced apoptosis compared with JEV-
infected and untransfected cells. Together, these effects
contributed synergistically to viral infection mainten-
ance. Thus, JEV sfRNA is able to block the host antiviral
response [104].
Murray Valley encephalitis virus
Murray Valley encephalitis virus (MVEV) is endemic to
Australia. Water birds are the main reservoir for this
virus, and the major mosquito vector is Culex annuliros-
tris. Human infection occurs through bites from infected
mosquitoes. Some people may experience a mild form of
the disease with symptoms such as fever, headaches,
nausea, vomiting, diarrhoea, macular rash and cough.
Neurological features may occur, but the majority of
MVEV infections are sub-clinical and do not produce
disease symptoms [105, 106].
The first detection of a MVEV sfRNA of 600 nt was
reported by Urosevic et al. [79] in the brains of C3H/HeJ
(flavivirus susceptible) and C3H/RV (flavivirus resistant)
infected mice (MVEV OR2 strain) at 3, 4 and 6 dpi.
MVEV sfRNA was also found in infected Vero cells. Al-
though the sfRNA hybridized with a fragment from a
MVEV cDNA clone, which corresponds to the 3′ ter-
minal region of the MVEV genome, the origin and role
of this RNA in viral replication were not defined [79].
Later, Pijlman et al. [82] demonstrated the sfRNA pro-
duction in cell lines infected with several flaviviruses,
among which were MVEV and Alfuy virus (a subtype of
MVEV). Specifically, BHK-21 cells infected with MVEV
and Alfuy virus had sfRNA species of approximately
500 nt. Therefore, independent of cell source, MVEV
infection can produce sfRNAs. However, the role of
these molecules in MVEV replication requires further
exploration.
Yellow fever virus
Yellow fever virus (YFV) is the aetiological agent of a
viral haemorrhagic fever transmitted by Aedes aegypti
mosquitoes in Africa and Central and South America.
YFV infection causes significant morbidity and mortality
in Africa. The clinical spectrum of yellow fever ranges
from subclinical infection to systemic disease. The
acute infection may induce high fever, chills, intense
headache, malaise, generalized myalgia, nausea and
vomiting [107, 108].
The first report of sfRNA generation during YFV in-
fection was described by Pijlman et al. [82]. In BHK-21
cells infected with YFV, a sfRNA with approximately
300 nt derived from the 3′ UTR was first identified by
Northern blot hybridization. Later, Silva et al. [109] de-
scribed the molecular mechanism behind YFV sfRNA
production. In mammalian cell lines (BHK-21, Vero E6,
SW13), YFV (YFV-17D strain) infection generated three
sfRNAs termed RNA A (630 nt), RNA B (330 nt, also
called sfRNA1) and RNA C (235 nt, also called sfRNA2),
but in YFV-infected mosquito cells (C6/36), only
sfRNA1 was detected. To investigate the role of XRN1
in the sfRNA production, YFV-infected SW13 cells were
transduced with lentiviruses expressing shRNA to si-
lence XRN1 transcripts. The production of sfRNA after
XRN1 silencing was reduced approximately 90 %. These
results were confirmed in vitro by incubating purified
XRN1 with the YFV template. The viral RNA structure
required for sfRNA generation was identified by disrupt-
ing the SL-E region in the 3′ UTR of YFV RNA because
the 5′ end of sfRNA1 and sfRNA2 are located a few nu-
cleotides upstream of this region. When mutations were
introduced in SL-E region, which is part of a pseudoknot
structure, no sfRNA was detected in BHK-21 cells in-
fected with the YFV mutants. Thus, in both mammalian
and insect cells, a pseudoknot RNA structure in the 3′
UTR of the YFV genome is essential for XRN1 stalling
and sfRNA generation [109].
Further considerations on flavivirus-derived
sfRNAs and miRNAs
Pijlman et al. [82] identified the production of sfRNA
species as a unique feature of the flavivirus genus. Produc-
tion of sfRNA was not observed during the infection of a
virus belonging to another genus of the Flaviviridae family
[82], although a similar mechanism based on the stalling
of XRN1 was proposed to be involved in the generation of
much longer non-coding RNAs (~9.6–12.5 kb) in the case
of hepatitis C and bovine viral diarrhoea viruses [77]. An-
other flavivirus investigated by Pijlman et al. [82] was
Saumarez Reef virus (SRV), which is transmitted by ticks
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but cannot induce encephalitis. SRV also produces a
sfRNA of approximately 500 nt, but the role of this mol-
ecule in SRV replication was not investigated [82]. In fact,
all members of the flavivirus genus that have been investi-
gated to date regarding the production of sfRNAs during
infection (DENV, YFV, MVEV, WNV, JEV, SRV, TBEV,
Modoc virus, Apoi virus, Rio Bravo virus, Montana myotis
leukoencephalitis virus, Yokose virus, cell-fusing agent
virus, Culex flavivirus) have shown positive results [75,
110], despite the fact that not all flaviviruses present the
same secondary structures in the 3′ UTR [111].
vsRNAs have also been identified in tick-borne flavi-
viruses. To elucidate the antiviral role of RNAi in ticks,
Schnettler et al. [112] studied the vsRNA profile of an
Ixodes scapularis-derived cell line (IDE8) either infected
with a tick-borne flavivirus (TBEV or Langat virus) or
transfected with the corresponding replicon. In both
cases, vsRNAs were for the most part 22 nt long, scat-
tered throughout the genome and mapped in similar
proportion to the sense and antisense strands. Addition-
ally, a higher frequency of vsRNAs was derived from the
5′ and 3′ ends of the genome. The knockdown of genes
identified by phylogenetic analysis as homologous to
either Dicer-2 or Ago2 followed by either Langat virus
infection or its replicon transfection allowed the identifi-
cation of Ago30 and Ago16 as mediators of antiviral ac-
tivity against this virus. In the same work, an inhibitory
effect of the sfRNA on the RNAi machinery was also re-
ported [112].
In addition to the ones that have been previously cited,
many in silico predicted flavivirus-derived miRNAs can
be found in the Vir-Mir database. The methodology used
to build up the Vir-Mir database was based on the pre-
diction of candidate hairpin structures compatible with
the characteristics of known pre-miRNAs from the gen-
omic sequences of 2266 viruses available at the time in
the GenBank database. Afterwards, additional filters also
based on the characteristics of known miRNAs, such as
GC content, core minimum free energy (MFE), hairpin
MFE and ratio of core MFE to hairpin MFE, were ap-
plied to reduce the number of false positives [113]. In
total, the Vir-Mir database lists 171 flavivirus-derived
miRNA candidates that have been predicted using this
strategy [114].
Furthermore, a study by Brackney et al. [115] notes
the role of RNAi in WNV genetic diversification in in-
fected Culex (pipiens) quinquefasciatus mosquitoes. The
midgut of infected mosquitoes (NY99 strain) collected at
7 and 14 days post infection (dpi) was used in the con-
struction of a small RNA library. The size of the sRNAs,
which mapped to WNV genome, ranged from 19 to
29 nt, but the most abundant sizes were 20, 21 and
22 nt. Considering that the RNAi machinery is
sequence-specific, and mutations in the target dsRNA
sequence can compromise its efficiency, the target re-
gions of RNAi in the WNV genome were evaluated. Mu-
tations were detected in both viral targets: NS5 (7 and
14 dpi samples) and 3′ UTR (14 dpi samples). In conclu-
sion, the authors suggest a correlation between RNAi
machinery activity and viral evolution (positive selec-
tion), which reinforces the importance of the mosquito
to WNV diversification [115].
As a final remark, it is important to remember that
the different flaviviruses present variations in their 3′
UTRs, such as deletions and/or duplications of con-
served structures. Just to cite an example, Bryant et al.
[116] reported the existence of a 16 nt duplication,
which created in tandem repetition of a conserved hair-
pin, stem-loop and pseudoknot RNA structure, in 19
YFV isolates from South America [116]. Taking this into
consideration and the fact that sfRNAs may be the
source of viral miRNAs by a non-canonical pathway, as
previously suggested by Hussain et al. [15] and Roby et
al. [75], variations in the 3′ UTR may have an impact on
the different expression patterns of non-coding RNAs
observed for the different viruses.
Human and murine miRNAs modulated during
flavivirus infection
Recently, several studies have shown an intimate rela-
tionship between RNA virus infection, miRNAs and host
response [117, 118]. During viral infection, cells can alter
the miRNA profile involved in physiological functions
and establish an antiviral state. Human miRNAs have
been described as regulators of gene expression in viral
replication and host immune responses [119]. For this
topic, all available information on human and murine
miRNAs produced in response to flavivirus infection
was gathered. However, only the miRNAs with con-
firmed function through biological assays, such as the
use of mimic miRNAs, miRNAs inhibitors and/or lucif-
erase reporter vectors, are presented in Table 2. The use
of an asterisk to identify the passenger strand has been
replaced in miRBase by the use of either -5p or -3p
which identify the arm of the hairpin precursor from
which the mature miRNA originates. However, the no-
menclatures seen in the text follow the information as
presented in the original articles.
West Nile virus
In the case of WNV (385-99 strain) infection, many dif-
ferent cellular miRNAs have been identified as differen-
tially expressed in infected cells (HEK293 and SK-N-MC
cell lines) compared with uninfected controls, using
miRNA-specific microarrays. Interestingly, the profile of
differentially expressed miRNAs in infected cells and un-
infected cells treated with interferon is quite different,
which indicates that the differentially expressed miRNAs
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are not simply a result of the interferon-induced anti-
viral response. The most highly expressed miRNA,
Hs_154, identified in this study was shown to be consist-
ently up-regulated independent of the infected cell line
(HEK293, SK-N-MC, Huh7, Huh7.5) and in the brains
of infected mice at 11 dpi, temporally correlating with
pathogenesis. Cells transfected with a mimic of the ma-
ture dsRNA and subsequently infected with WNV had
lower viral titres at 2 and 3 dpi, suggesting an antiviral
role for Hs_154. A time-course experiment that was car-
ried out in HEK293 cells infected with WNV showed
that Hs_154 up-regulation could be detected at 36 hpi
and was stronger at 48 hpi, when strong cytopathic ef-
fect associated with apoptosis can already be observed,
suggesting that its induction occurs in response to viral
infection. However, treating cells with different inducers
of antiviral pathways, such as poly I:C, IFN or another
flavivirus (DENV), did not induce Hs_154 miRNA ex-
pression. To identify Hs_154 miRNA targets, RISC im-
munoprecipitation was carried out followed by a search
for a match in the 3′ UTR of the enriched mRNAs to
the seed sequence of Hs_154. Among the identified po-
tential targets, two were selected for further analysis:
CCCTC binding factor (CTCF) and EGFR-coamplified
and overexpressed protein (ECOP). The 3′ UTRs of
these mRNAs were inserted downstream of a luciferase
reporter vector and transfected into cells followed by
WNV infection or the concomitant transfection of a
mimic of Hs_154 miRNA. In both cases, WNV infection
or Hs_154 mimic co-transfection, a decrease in the ex-
pression of luciferase was observed, which demonstrates
these mRNAs are targeted by the Hs_154 miRNA. Add-
itionally, the infection of cells that had been transfected
with either CTCF- or ECOP-expressing vectors resulted
in a decrease in the cleavage of poly (ADP-ribose) poly-
merase, a substrate for caspase, and also in TUNEL
staining. The same results were observed when cells
were transfected with an inhibitor of Hs_154 miRNA.
As both proteins are known to possess antiapoptotic ac-
tivity, and given the results obtained, their targeting by
Hs_154 miRNA can be assumed to play an important
role in the apoptosis observed during viral infection.
The authors conclude that although the inhibitory effect
of Hs_154 miRNA on viral replication implies an anti-
viral host response, its association with apoptosis, mainly
when considering infection of the central nervous system,
may represent an adverse side effect for the host [120].
Regarding the host miRNA antiviral response, Slonchak
et al. [121] evaluated WNV (Kunjin strain) infection in
mammalian cells (HEK293) and mice. miRNA expression
analysis by RNAseq, qRT-PCR, and Northern blot re-
vealed that three host miRNAs were significantly up-
regulated during infection (miR-1271-5p, miR-532-5p and
miR-1307-3p). To investigate the role of these three miR-
NAs in WNV replication, HEK293 cells were first trans-
fected with miRNA-specific mimics, nonspecific mimics
or inhibitors and then infected. Only in the cells trans-
fected with the miR-532-5p mimic was viral titre
Table 2 Function of human and murine miRNAs modulated during flavivirus infection
Flavivirus miRNA Host system Function Reference
WNV Hs_154 HEK293, SK-N-MC, Huh7, Huh7.5 and
mouse brain
Modulates the apoptotic response Smith et al., [120]
WNV miR-532-5p HEK293 and mouse brain Suppresses genes SESTD1 and TAB3 Slonchak et al., [121]
DENV-2 miR-146a PBMC and THP-1 Dampens IFN-β production by targeting TRAF6 Wu et al., [118]
DENV-1, 2 and 3 miR-30e* U937, HeLa and PBMC Up-regulates IFN-β and ISG expression Zhu et al., [123]
DENV-2 miR-150 PMBC Regulates SOCS1 expression Chen et al., [126]
DEN-2 miR-223 EAhy926, HepG2 and Vero Represses STMN1 Wu et al., [127]
DENV-2 and 4 Let-7c Huh7 Modulates BACH1 and HO-1 expression Escalera-Cueto et al., [124]
JEV miR-29b BV-2 and primary microglial cells Microglia activation by targeting TNFAIP3 Thounaojam et al., [130]
JEV miR-155 BV-2, mouse primary microglial cells,
mouse and human brains
Inhibits SHIP1 expression and promotes
IFN-β expression
Thounaojam et al., [131]
JEV miR-155 CHME3 Represses IFN-β production Pareek et al., [132]
JEV miR-15b BV-2, U251, HeLa and mouse brain Represses RNF125, a RIG-I inhibitor Wu et al., [127]
JEV miR-146a CHME3 Down-regulation of TRAF6 expression Sharma et al., [133]
Abbreviations: BACH1 BTB and CNC homology 1, basic leucine zipper transcription factor 1, DENV dengue virus, HO-1 haeme oxygenase-1, IFN interferon, JEV
Japanese encephalitis virus, RIG-I retinoic acid-inducible gene 1, RNF125 ring finger protein 125, SESTD1 SEC14 and spectrin domains 1, SHIP1 Src homology
2-containing inositol phosphatase 1, SOCS1 suppressor of cytokine signalling 1, STMN1 stathmin 1, TAB3 TGF-beta activated kinase 1/MAP3K7 binding protein 3,
TNFAIP3 tumour necrosis factor alpha-induced protein 3, TRAF6 TNF receptor-associated factor 6, WNV West Nile virus
Host system: BV-2 (Mouse microglial cell line), CHME3 (Human brain microglial cell line), EAhy926 (Human vascular endothelial cell line), HEK293 (Human embryonic
kidney 293 cell line), HeLa (Human cervical carcinoma cell line), HepG2 (Human hepatocellular carcinoma cell line), Huh7 and Huh7.5 (Human hepatocarcinoma cell line),
PBMC (Human peripheral blood mononuclear cells), SK-N-MC (Human neuroblastoma cell line), THP-1 (Human monocytic cell line), U251 cells (Human astrocytoma cell
line), U937 (Human leukaemic monocyte lymphoma cell line) and Vero (African green monkey kidney cell line)
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significantly reduced. Opposing results were observed
when the cells were transfected with the miR-532-5p in-
hibitor. The interaction between miR-532-5p and a puta-
tive site in the WNV RNA genome was investigated
through computational screening using the RNAhybrid
software. Although this analysis predicted two potential
binding sites, which were experimentally assessed by a lu-
ciferase reporter assay, no functional effect on expression
of luciferase was observed. These results suggested that
miR-532-5p has a host target. To identify possible
miR-532-5p targets in human genes, the whole gen-
ome was evaluated by computational prediction asses-
sing several features, such as evolutionary
conservation of sites (miRDB, TargetScanHuman),
seed region complementarity (Diana Micro-T, micr-
roRNA.org) and thermodynamics of duplexes (Target-
Miner, RNA22). Ten candidates (CPEB3, FAM116A,
SESTD1, RASSF5, GBP1, ZNF536, RAB11A, ARMC8,
SMAD2 and TAB3) were selected based on simultaneous
prediction by at least 5 different algorithms. To validate
the predicted targets, they were evaluated in WNV-
infected and uninfected HEK293 cells using qRT-PCR.
The mRNA levels of TGF-β activated kinase 1/MAP3K7
binding protein 3 (TAB3) and SEC14 and spectrin do-
mains 1 (SESTD1) decreased significantly in WNV infec-
tion. SESTD1 is important for cellular Ca2+ influx, and
TAB3 is required to NF-kB signalling. The interaction be-
tween miR-532-5p and its targets (TAB3 and SESTD1)
was further validated by Western blot, use of miR-532-5p
mimics and luciferase assays. Similar to the qRT-PCR re-
sults, TAB3 and SESTD1 protein expression was signifi-
cantly decreased during infection. Similar results were
observed in non-infected cells treated with a miR-532-
5p mimic. Finally, the luciferase reporter assays con-
firmed targeting of the TAB3 and SESTD1 3′ UTRs
by miR-532-5p. In conclusion, these results indicate
that WNV infection induces cellular miR-532-5p,
which in turn affects the host antiviral response
[121].
Concerning WNV infection (NY99 strain), Kumar and
Nerurkar [122] examined the miRNA expression in the
brains of infected mice at the peak viral load (8 dpi)
using a qPCR array. Compared with mock-infected mice,
36 miRNAs were up-regulated and 103 down-regulated
by at least 2-fold. Some presented a fold change higher
than 10. The up-regulated miRNAs include let-7a and
miR-99a and the down-regulated include miR-196a,
miR-470, miR-21*, miR-208a, miR-683, miR-184, miR-
693-3p, miR-202-3p, miR-429, miR-878-3p and miR-327.
Many of the miRNAs that were identified as differen-
tially expressed were associated with neurodegenerative
diseases (Parkinson’s, Alzheimer’s and Huntington’s dis-
eases) and other virus-mediated neurological diseases,
suggesting the modulation of common neurological
pathways. Target prediction and analysis of the miRNA-
mediated networks indicated cell death and survival,
immune-cell trafficking, cell-mediated immune response
and inflammatory response as the leading pathways as-
sociated with the modulation observed during infection.
Because all these pathways are associated with WNV
pathogenesis in this animal model, the identified miR-
NAs may play significant roles during viral infection.
Additionally, when the mRNA expression profile was
analysed, an inverse correlation between the modulated
miRNAs and target neuroinflammatory genes was found,
supporting a role for them in disease pathogenesis [122].
Dengue virus
Up-regulation of human miR-146a was found in human
primary monocytes and THP-1 monocytes infected with
DENV-1 (Hawaii strain), DENV-2 (New Guinea C strain),
or DENV-3 (H241 strain). Investigating the role of miR-
146a in DENV-2 infection, Wu et al. [118] observed that
this miRNA promoted viral replication even at different
multiplicities of infection (MOI). The molecular mechan-
ism behind the proviral role of miR-146a involves the
down-regulation of IFN-β through targeting of TNF re-
ceptor associated factor 6 (TRAF6), an adaptor in the IFN
pathway signalling. This was the first study that showed
the role for a host miRNA in DENV infection [118].
Similarly, taking into account that miR-30e* promotes
NF-kB activation, which is essential for antiviral innate
immune activation, Zhu et al. [123] investigated its role
in DENV infection. HeLa cells were infected with
DENV-1 (Hawaii strain), DENV-2 (New Guinea C
strain), or DENV-3 (H241 strain). Six hours after infec-
tion, the relative miR-30e* expression was significantly
increased in infected cells regardless of serotype. Similar
results were observed in U937 cells and PBMCs infected
with DENV. When a miR-30e* mimic was transfected
into HeLa, U937 and PBMC cells followed by DENV-2
infection, viral replication was suppressed. On the other
hand, IFN-β mRNA expression and IFN-β secretion in
the cell culture supernatant was increased. Additionally,
DENV-2 replication was rescued when miR-30e* was
silenced. Taking into account the association between
IFN-β production and NF-kB activation during viral
infection, the effect of miR-30e* on the gene expression
of NF-kB pathway components was investigated. A lucif-
erase reporter plasmid construction carrying the 3′ UTR
sequence of IkBα (nuclear factor of kappa light polypep-
tide gene enhancer in B-cells inhibitor, alpha) mRNA
(an inhibitor of NF-kB) was transfected into HeLa and
U937 cells. When these cells were co-transfected with a
miR-30e* mimic, the luciferase activity was suppressed.
In conclusion, during DENV infection, miR-30e* is an
important regulator of antiviral response inhibiting virus
replication [123].
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Furthermore, to investigate the human miRNA modu-
lation during DENV infection, Huh7 cells were infected
with DENV-2 (New Guinea C strain), and the miRNA
profile was analysed with a GeneChip miRNA Array.
From 846 human miRNAs, nine (let-7c, miR-92b*, miR-
130b, miR-140-3p, miR-149*, miR-181c*, miR-374a*,
miR-453, miR-1268) were identified as differentially
expressed. Several targets could be predicted in the
DENV-2 genome for the differentially expressed miR-
NAs, although the miRNA with the highest scoring
targets was let-7c. Moreover, it was overexpressed at dif-
ferent times post infection (12, 24 and 48 hpi) in Huh7
as well as in U937-DC-SIGN cells. The predicted target
for let-7c in the viral genome was NS1 (which is highly
conserved in different DENV-2 strains) and NS4B
(which is not conserved). However, when Huh7 cells
were pretreated with a let-7c mimic and then infected
with DENV-2 or DENV-4, viral replication and NS1 pro-
tein production were significantly reduced. The opposite
was observed when let-7c was inhibited. Curiously, no
targets for let-7c were found in the DENV-4 (V3361-
1956 strain) genome. These results suggested that the
let-7c target may be a human mRNA involved in anti-
viral response. TargetScan identified BACH1, a tran-
scription inhibitor, as one of the genes predicted to have
target sequences for let-7c. Experiments employing let-
7c mimics or let-7c inhibitor confirmed BACH1 as a let-
7c target; their expression levels were shown to be
negatively correlated. As a consequence of BACH1
down-regulation by let-7c, the heme oxygenase-1 gene
may be overexpressed, contributing to the development
of an anti-inflammatory microenvironment, which may
antagonize the oxidative stress response induced by the
infection [124]. It is worth noting that in WNV infec-
tions, down-regulation of let-7c expression was observed
in the brains of infected mice [122].
One of the features of DHF/DSS is the occurrence of a
cytokine storm, which leads to serious plasma leakage.
Two studies have investigated this feature with regard to
the human miRNA profile induced by DENV infection
[125, 126]. In the first, Qi et al. [125] investigated
whether the excessive secretion of cytokines during
DENV-2 infection is a result of miRNA activity on cyto-
kine genes or regulators. To answer this question,
PBMCs from healthy donors were infected with DENV-
2 (New Guinea strain). The cytokines that were shown
to be most highly expressed in infected cells were CCL5,
IL-6 and IL-8 (6 and 12 hpi). The expression profile of
infected and uninfected cells was evaluated using a
miRNA microarray, and 16 miRNAs were reported to be
up-regulated (miR-4290, miR-4279, miR-625*, miR-let-
7e, miR-1290, miR-33a, miR-3686, miR-378, miR-1246,
miR-767-5p, miR-320c, miR-720, miR-491-3p, miR-3647,
miR-451 and miR-4286) and 4 down-regulated (miR-
106b, miR-20a, miR-30b and miR-3653) during dengue
infection. The differential expression of most of the miR-
NAs identified in the microarray analysis was confirmed
by qRT-PCR, but none of them were evaluated for func-
tion. Three different online databases (Sanger miRBase,
miRanda and TargetScan) were used to predict target
genes for the differentially expressed miRNAs. Common
targets identified by the different databases were submit-
ted to ingenuity pathway analysis software, and several
cell processes were identified to be associated with the
predicted targets, such as signal transduction, cell re-
sponse to stimulus, biological regulation, and metabol-
ism. Finally, to evaluate the relationship between
cytokine expression and miRNA profile, a sequence
homology search was carried out between the mRNAs
of cytokine genes and the differentially expressed miR-
NAs. This analysis identified IL-6 and CCL3 as potential
targets of miR-let-7e and MIF, CCL5 and CXCL1 as po-
tential targets of miR-451, miR-106b and miR-4279, re-
spectively. The lower levels of miR-106b and the higher
levels of expression of CCL5 are compatible with a dere-
pression mechanism. However, this mechanism is not
able to explain the high levels of miR-let-7e and its tar-
get cytokine genes (CCL3 and IL-6). The authors also
identified epigenetic regulators as the potential targets of
miR-let-7e (EZH2) and miR-30b (methyltransferase 3A).
Therefore, they hypothesize that the high levels of some
cytokines may be a consequence of targeting the ele-
ments involved in epigenetic processes [125]. A report
by Chen et al. [126] further investigated the relationship
between cytokine and miRNA expression during DENV
infection by focusing on suppressor of cytokine signal-
ling 1 (SOCS1), a negative regulator of several cytokines.
In this case, however, the role of DENV-induced human
miRNA in the regulation of SOCS1 expression in DF
and DHF patients was investigated. Significantly higher
SOCS1 mRNA was observed in leukocytes from DF
compared with DHF patients. Additionally, when
PBMCs from healthy donors were infected with DENV-
2 (New Guinea strain), SOCS1 mRNA expression was
shown to be increased in DENV-2-infected cells com-
pared with mock-infected cells, especially in CD14+ cells
(monocytes and macrophages). A bioinformatics search
for miRNAs that target the SOCS1 3′ UTR resulted in
11 candidates (miR-15a, miR-20, miR-21, miR-96, miR-
126, miR-146, miR-150, miR-181a, miR-155, miR-221
and miR-57). All of them were evaluated by qRT-PCR,
but only miR-150 was up-regulated in DHF samples.
Interestingly, SOCS1 mRNA expression in leukocytes
from DHF and DF patients was inversely correlated with
miR-150 expression. In the DHF patients, SOCS1 ex-
pression was down-regulated and miR-150 was up-
regulated, and the inverse was observed in DF samples.
To confirm the association between SOCS1 and miR-
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150 expression, PBMCs from healthy donors were in-
fected with DENV-2 and then transfected with miR-150
mimics. As a result, the SOCS1 mRNA expression was
significantly repressed. In conclusion, the authors
showed for the first time that the pathogenesis of DHF
is associated with the repression of SOCS1 concomitant
to the increased expression of miR-150 [126].
Evaluating the miRNA profile in a human vascular
endothelial cell line (EAhy926) infected with DENV-2
(TR1751 strain) by microarray and qRT-PCR, 12 miRNA
candidates were found to be up-regulated (miR-3178,
miR-324-3p, miR-937, miR-3195, hsv1-miR-H6-3p,
kshv-miR-K12-12*, let-7a-2*, miR-20b*) and down-
regulated (miR-21*, miR-2116, miR-142-3p, miR-223).
Among the down-regulated candidates, miR-223 showed
a 30 % reduction when compared to uninfected cells.
Similar results were observed in other mammalian cells
(HepG2 and Vero). To investigate the involvement of
miR-223 in DENV-2 replication, this miRNA was over-
expressed or reduced using a plasmid transfection ap-
proach in cell culture. When miR-223 was inhibited,
there was increase in viral titre in supernatants and
lysates of infected EAhy926 cells. Employing miRNA
target prediction software programs (miRanda, PicTar,
TargetScan), the candidate stathmin 1 (STMN1), a
microtubule destabilizer, was identified and validated by
luciferase reporter assay. Concomitant with miR-223
down-regulation, there was a 63-fold increase in the
level of STMN1 mRNA in infected cells. Likewise, the
overexpression of STMN1 increased viral replication in
culture supernatants and lysates. In conclusion, dengue
infection was able to decrease miR-223 levels, which in
turn increases STMN1 protein expression and improves
virus replication, suggesting a potential antiviral role for
this miRNA [127].
To identify miRNAs related to dengue pathophysio-
logical mechanisms, the miRNA profile from blood sam-
ples of dengue-infected patients was compared with that
of healthy individuals and patients with influenza. As a
result, 12 miRNAs (miR-1204, miR-1225-5p, miR-3121-
3p, miR-4259, miR-4327, miR-450b-5p, miR-491-5p,
miR-499a-3p, miR-512-5p, miR-615-5p, miR-624-5p,
miR-892b) showing an expression profile specific to
acute dengue and fourteen miRNAs (miR-99b-5p, miR-
218-5p, miR-296-5p, miR-499a-5p, miR-520d-3p, miR-
520 g, miR-524-3p, miR-544a, miR-548 h-5p, miR-625-
3p, miR-649, miR-1181, miR-1277-3p, miR-3937) that
were similarly altered in dengue and influenza were
identified. Additionally, 17 miRNAs presenting consist-
ent differential expression between different clinical pre-
sentations (dengue fever, dengue fever with liver
complications or dengue fever with haemorrhagic fever),
which can be observed during dengue infection, were
also identified. For more detailed information, see [128].
In the pathway analysis of the panel of 12 miRNAs
showing acute dengue-specific expression, the most af-
fected pathways were the PI3K-AKT survival pathway,
JAK-STAT and cytokine-cytokine receptor signalling.
This result is consistent with available data on some of
the targets of altered miRNAs, such as miR-1204, which
is related to cell death induction, miR-491-5p, which is a
negative regulator of p53 and Bcl-XL, and miR-512-5p,
which represses nucleotide-binding oligomerization domain
containing 2 (NOD2). No functional characterization ex-
periments were carried out [128].
Taken together, the research studies cited above reveal
that the different human miRNAs produced during DENV
infection may have proviral [118] and antiviral [123, 124]
roles or are associated with the severity of disease through
regulation of cytokine expression [125, 126].
Japanese encephalitis virus
JEV infection targets the central nervous system and in-
duces a profound neuroinflammation. To evaluate the
role of host miRNAs in JEV infection, Zhu et al. [129]
performed a deep-sequencing analysis of JEV-infected
astrocytes (U251). Among the miRNAs observed to be
up-regulated during infection, miR-15b was chosen for
further investigation because it had been previously
linked to inflammation pathways. miR-15b expression
was shown to be induced after JEV infection (U251 and
BV-2 cells) in a time- and MOI-dependent fashion. In
addition, miR-15b mimics induced a higher expression
of several inflammatory cytokines (TNF-α, IL-1β, IL-6,
CCL5, IL-12p70) and ISGs (IFN-β, ISG56, OAS1, MxA
and ISG15) while cells treated with a miR-15b inhibitor
exhibited the opposite results. Additionally, with mir-
15b mimics or inhibitors, no effect on viral replication
was noted. In search of cellular targets of miR-15b, a
negative regulator of retinoic acid-inducible gene 1
(RIG-I), ring finger protein 125 (RNF125), was identified
by computational prediction. This finding was experi-
mentally confirmed as well as the modulation of RIG-I
expression during JEV infection. The results suggested
an inverse correlation of miR-15-b and RIG-I expression
with RNF125. The effect on the inflammatory response
was also evaluated by measuring cytokine production
after inducing or repressing the expression of miR-15b
and/or RNF125 followed by JEV infection. The results
show a direct link among miR-15b up-regulation during
JEV infection, RNF125 suppression and inflammatory
cytokine response. To validate the in vitro results, the
miR-15b study was extended to a mouse model of JEV
infection. In infected mice, high miR-15b and low
RNF125 levels were found. In the presence of a miR-15b
antagomir, the concentration of IL-1β, IL-6 and CCL2 in
brain samples was significantly decreased. In addition,
the antagomir treatment improved mouse survival,
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controlled viral replication and prevented brain damage.
In summary, miR-15b is a strong candidate for thera-
peutic intervention [129].
Using a miRNA PCR array covering 84 miRNA se-
quences, Thounaojam et al. [130] investigated the JEV-
induced (GP78 strain) mouse microglial (BV-2 cell line)
miRNA profile. The assay results revealed four highly
up-regulated miRNAs (up to 60-fold change) at 24 hpi:
miR-29b, miR-155, miR-301a and miR-301b. Because
miR-29b showed the highest modulation and has already
been assigned to a pro-inflammatory role, it was selected
for further investigations. miR-29b up-regulation was
confirmed in JEV-infected primary microglial cells (from
BALB/c mice). Furthermore, tumour necrosis factor
alpha-induced protein 3 (TNFAIP3), a negative regulator
of NF-kB and the presumed target of mir-29b, was
shown to be down-regulated at the mRNA and protein
levels. Treatment of infected cells with a miR-29b mimic
or an anti-miR-29b confirmed the targeting of TNFAIP3.
The miR-29b production during in vitro JEV infection
was shown to be associated with an increase in the
expression of microglial activation markers, such as in-
ducible nitric oxide synthase and cyclooxygenase-2, pro-
inflammatory cytokine production and NF-kB pathway
activation. Thus, it can be inferred that miR-29b contrib-
utes to production of pro-inflammatory mediators and
the activation of microglial cells, a key event in JEV-
induced neuroinflammation [130]. Next, Thounaojam et
al. [131] evaluated the role of host miR-155 in the regu-
lation of the inflammatory response during JEV (GP78
strain) infection. miR-155 overexpression was observed
in the brain of JEV-infected mice (3, 5 and 7 dpi -
BALB/c), in post-mortem human brain samples of JEV
confirmed cases and in JEV-infected BV-2 and primary
microglial cells (24 hpi). Employing bioinformatics tools
(Pictar and TargetScan), the Src homology 2-containing
inositol phosphatase 1 (SHIP1) mRNA was predicted to
be targeted by miR-155. In JEV-infected BV-2 cells and
in the brains of infected mice, a time-dependent de-
crease in the expression levels of SHIP1 mRNA was
observed. Similarly, addition of a miR-155 inhibitor to
JEV-infected BV-2 cells and mice led to an increase
in SHIP1 expression. Thus, JEV infection resulted in
the up-regulation of miR-155 and down-regulation of
SHIP1 mRNA expression. JEV infection promotes the
secretion of pro-inflammatory cytokines, which is re-
lated to microglia activation and neuronal death in
the mouse brain. Infected mice that were treated with
an inhibitor of miR-155 showed a decrease in the pro-
duction of IFN-β, TNF-α, MCP-1 and IL-6, an increase in
SHIP1 expression, a decrease in symptoms associated to
JEV infection and an increase in mouse survival. In
conclusion, the authors suggest miR-155 as a potential
therapeutic target in JEV infection, as it promotes
inflammation by inhibiting SHIP1, a negative regulator of
IFN-β [131].
Pareek et al. [132], on the other hand, identified miR-
155 as an inhibitor of JEV replication and activation of
microglia cells. When human microglial cells (CHME3)
infected with JEV (P20778 strain) were evaluated with a
global miRNA array to identify differentially expressed
miRNAs, miR-155 was shown to be down-regulated
early in infection (6 hpi) but was up-regulated later on
(24 and 48 hpi). When miR-155 was overexpressed in
CHME3 cells, through miR-155 mimic transfection,
followed by JEV infection, NS1 protein, JEV RNA and
JEV titre were significantly reduced compared to con-
trols (mimic control transfection followed by JEV infec-
tion). In addition, human microglial cells overexpressing
miR-155 that were infected with JEV showed a reduction
in IFN-β expression, ISG transcripts, IRF8 expression
and NF-kB activation compared to JEV infection alone
[132]. The contradictory results obtained by Pareek et al.
[132] and Thounaojam et al. [131] may be attributed to
differences in the cells studied (CHME3 versus BV-2
and mouse brain) or in the JEV strains employed in the
different studies (P20778 versus slow-growing GP78)
and/or to the amount of miR-155 produced during the
infections [132].
Pareek et al. [132] also studied miR-146a, which in an
initial analysis had been shown to be up-regulated at an
early stage (6 hpi) and down-regulated at later time
points (24 and 48 hpi) post infection; however, no sig-
nificant effect was attributed to it in this study. Sharma
et al. [133], on the other hand, described high levels of
miR-146a after the infection of CHME3 cells with JEV
JaOArS982 strain (24 hpi). To verify if this was a strain-
specific effect, miR-146a production in response to the
infection of CHME3 cells with two different JEV strains,
P20778 Vellore and JaOArS982, was compared. The re-
sults from Sharma et al. [133] regarding miR-146a
expression after JEV P20778 strain infection were con-
sistent with those previously obtained by Pareek et al.
[132], confirming this was a strain-specific effect. Fur-
ther studies on the effects of the miR-146a increase in
JEV-infected CHME3 cells showed that this miRNA
overexpression was associated with increased amounts
of JEV RNA, especially at 24 hpi (JaOArS982). In
addition, when cell cultures were treated with anti-miR-
146a, prior to JEV infection (JaOArS982), the viral copy
number decreased, suggesting a positive effect of miR-
146a on JEV replication. TRAF6, IRAK1, and IRAK2,
which are involved in NF-kB pathway activation, are re-
ported to be miR-146a targets. Both JEV infection
(JaOArS982) and miR-146a overexpression resulted in
the down-regulation of these genes. Silencing of miR-
146a prior to JEV infection (JaOArS982), on the other
hand, was able to rescue their expression. In addition,
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miRNA-146a targeted the signal transducer and activa-
tor of transcription 1 (STAT1), which is important in
promoting interferon-stimulated response elements and
ISG expression. Summing up, in this model of JEV infec-
tion (JaOArS982 strain), miR-146a up-regulation was
shown to be associated with inhibition of the NF-kB
pathway activation and disruption of antiviral pathway
signalling [133].
Finally, Cai et al. [134] investigated the host miRNA
production in JEV-infected porcine kidney epithelial cells
(PK15). Among the 132 differentially expressed (≥ 2-fold
change) miRNAs, 59 % were up-regulated in infected
compared to uninfected cells, and 41 % were down-
regulated. Many of these had already been reported to
be modulated in response to other viral infections.
Target prediction of the differentially expressed miR-
NAs and gene ontology analysis of the predicted tar-
gets was carried out, but no functional assays were
performed [134].
Closing remarks on host miRNAs modulated during
flavivirus infection
It is likely that most of the human and mouse flavivirus-
induced miRNAs are produced in a virus-specific and
host-dependent fashion. Currently, the only human
miRNA induced by different flaviviruses, including JEV
and DENV, is miR-146a, which was also found in other
virus infection models, such as vesicular stomatitis virus
[135], Hendra virus [136], enterovirus [117], hepatitis B
virus [137, 138] and human neurotrophic viruses [139],
among others. Mammalian cells infected with entero-
virus 71 [117], dengue virus 2 [118], JEV [133] or vesicu-
lar stomatitis virus [135] produced miRNA-146a. This
miRNA facilitates viral replication by targeting TRAF6,
which has an essential role in the signalling pathways of
Toll-like or RIG-I like receptors [117, 118, 133, 135]. Al-
though common miRNAs have been identified as differ-
entially expressed in the studies of Kumar and Nerurkar
[122] and Cai et al. [134] in WNV and JEV infection
models, respectively, none of these were confirmed
through functional assays, such as the use of miRNA
mimics or inhibitors.
In sum, identifying virus-induced human miRNAs
may be a good approach to search for biomarkers that
could be used for disease diagnosis, prevention and
treatment [140].
Conclusion
In conclusion, regarding the Flavivirus genus, by the
time this review was finished, there was experimental
evidence for the existence of viral miRNAs derived from
WNV and DENV and viral sfRNA from all members of
this genus where it has been investigated.
The identification of viral miRNAs with immunomod-
ulatory activities increases the potential targets for thera-
peutic approaches. On the other hand, molecules that
“neutralize” virus-derived miRNAs could be used to
eradicate miRNA-mediated escape, favouring the course
of the immune response to the viral infection. Addition-
ally, finding viral mutants in miRNA sequences or vi-
ruses that are defective in the production of sfRNAs
may provide information for the rational development of
vaccines using attenuated flaviviruses. Moreover, the dis-
covery and characterization of viral miRNAs/sfRNAs
contribute to the development of tools for studying the
cellular mechanisms involved in virus-host interaction,
viral RNA turnover and viral pathogenicity associated
with flavivirus infection.
Both types of molecules, miRNAs and sfRNAs, are
strongly associated with the modulation of host cell gene
expression and immune response during flavivirus infec-
tion. Human miRNAs are also closely linked to the regula-
tion of viral replication. Taking this into account, both
human and viral miRNAs could play an important role as
biomarkers of viral infection prognosis and pathogenicity,
as well as diagnostic tools and potential therapeutic targets.
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